Vertex Pharmaceuticals IncorporatedVRTXNASDAQ
LOADING
|||
Cash Flow Under Pressure
Trending lower, below historical average, modest growth trend.
Left:
||||
Operating cash flow minus capital expenditures
Latest
$-790.30M
↓ 153% below average
Average (9y)
$1.48B
Historical baseline
Range
High:$3.93B
Low:$-790.30M
CAGR
+7.5%
Consistent expansion
| Period | Value | Change |
|---|---|---|
| 2024 | $-790.30M | -124.1% |
| 2023 | $3.28B | -16.5% |
| 2022 | $3.93B | +63.0% |
| 2021 | $2.41B | -19.5% |
| 2020 | $2.99B | +100.4% |
| 2019 | $1.49B | +27.2% |
| 2018 | $1.17B | +100.6% |
| 2017 | $585.52M | +226.1% |
| 2016 | $179.54M | +143.7% |
| 2015 | $-410.73M | - |